Gufic Biosciences is an API and finished-dose manufacturer based in India. It appears in 70 regulatory filings across 9 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), CDSCO (India) and INVIMA (CO). Its GMP standing is certified by EMA, CDSCO (India) and ANVISA (Brazil), among 6 authorities. Customs aggregates show $23.6M of exports covering 850 molecules to 67 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Dhar, India | 3043782814 |
| GUJARAT, India | Not on file |
| navsari, India | Not on file |
| Navsari, India | Not on file |
| kabilpore 396 424navsari navsari, India | Not on file |
| Mumbai India, Nigeria | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Lidocaine | SFDA (Saudi Arabia) | 1 |
| Miconazole | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 25 | None |
| CDSCO (India) | 15 | 4 |
| INVIMA (CO) | 10 | None |
| MINSA (CR) | 7 | None |
| BOMRA (BW) | 6 | None |
| TMDA (TZ) | 3 | 1 |
| EMA | None | 5 |
| ANVISA (Brazil) | None | 2 |
| NAFDAC (NG) | None | 2 |
| UZPHARM (UZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3.3M | 33 |
| 2025 | Not reported | $23.6M | 67 |
| 2024 | Not reported | $19.3M | 62 |
| 2023 | Not reported | $11.5M | 57 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Gufic Biosciences comes back tiered against every other supplier able to file there.
Start for free